合并症对前列腺癌特异性死亡率的影响:前瞻性观察研究
该研究基于瑞典1998至2012年118,543例前列腺癌患者,中位随访8.3年,评估合并症对不同治疗类型下前列腺癌特异性死亡率的影响。调整患者和肿瘤特征后,合并症对前列腺癌特异性死亡率的影响消失,但对其他原因死亡率的影响持续存在;进一步调整治疗类型后结果一致。
要点
- 调整患者和肿瘤特征后,合并症对前列腺癌特异性死亡率无影响。
- 合并症对其他原因死亡率的影响在调整后仍持续存在。
- 无论根治性手术或放疗,合并症增加似乎不显著影响死于前列腺癌的风险。
核心结论
- 该大型观察性研究提示,在考虑患者和肿瘤特征及治疗类型后,合并症影响其他原因死亡率但不影响前列腺癌特异性死亡率。
- 无论根治性治疗类型(根治性前列腺切除术或根治性放疗),合并症增加似乎不显著影响死于前列腺癌的风险。
- 人群比较有效性研究中观察到的肿瘤学结局差异可能不是治疗组间合并症分布不同的结果。
研究设计与样本
- 基于瑞典1998至2012年人群的观察性研究,纳入118,543例前列腺癌患者,中位随访8.3年(四分位距5.2至11.5年)。
- 按患者特征(婚姻状况、教育水平)、肿瘤特征(血清前列腺特异性抗原、肿瘤分级和临床分期)及治疗类型(根治性前列腺切除术、根治性放疗、雄激素剥夺治疗和观察等待)分类。
- 数据按Charlson合并症指数(0、1、2或≥3)分层,采用稳定逆概率加权调整临床患者和肿瘤特征及治疗类型。
- 使用Kaplan-Meier估计和Cox比例风险回归模型计算风险比。
主要发现
- 在完全未调整数据集中,观察到合并症增加对前列腺癌特异性死亡率和其他原因死亡率的影响。
- 调整患者和肿瘤特征后,合并症对前列腺癌特异性死亡率的影响消失,但对其他原因死亡率的影响持续存在。
- 进一步调整治疗类型后,仍未观察到合并症对前列腺癌特异性死亡率的影响,而对其其他原因死亡率的影响持续存在。
临床怎么用
- 在评估前列腺癌患者预后时,合并症对其他原因死亡的影响在调整后持续存在。
- 对于接受根治性前列腺切除术或根治性放疗的患者,合并症增加似乎不显著影响前列腺癌特异性死亡风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To determine the effect of comorbidity on prostate cancer (PCa)-specific mortality across treatment types. Patients and Methods These are the results of a population-based observational study in Sweden from 1998 to 2012 of 118,543 men who were diagnosed with PCa with a median follow-up of 8.3 years (interquartile range, 5.2 to 11.5 years) until death from PCa or other causes. Patients were categorized by patient characteristics (marital status, educational level) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stage) and by treatment type (radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and watchful waiting). Data were stratified by Charlson comorbidity index (0, 1, 2, or ≥ 3). Mortality from PCa and other causes and after stabilized inverse probability weighting adjustments for clinical patient and tumor characteristics and treatment type was determined. Kaplan-Meier estimates and Cox proportional hazards regression models were used to calculate hazard ratios. Results In the complete unadjusted data set, we observed an effect of increased comorbidity on PCa-specific and other-cause mortality. After adjustments for patient and tumor characteristics, the effect of comorbidity on PCa-specific mortality was lost but maintained for other-cause mortality. After additional adjustment for treatment type, we again failed to observe an effect for comorbidity on PCa-specific mortality, although it was maintained for other-cause mortality. Conclusion This large observational study suggests that comorbidity affects other cause-mortality but not PCa-specific- mortality after accounting for patient and tumor characteristics and treatment type. Regardless of radical treatment type (radical prostatectomy or radical radiotherapy), increasing comorbidity does not seem to significantly affect the risk of dying from PCa. Consequently, differences in oncologic outcomes that were observed in population-based comparative effectiveness studies of PCa treatments may not be a result of the varying distribution of comorbidity among treatment groups.
引用
- Rajan P, Sooriakumaran P, Nyberg T, et al. Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol. 2017. PMID: 28930493. doi:10.1200/JCO.2016.70.7794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。